Believe it or not, Pfizer’s drug Viagra was originally designed to treat cardiovascular problems. Early on in clinical trials, men taking the drug became…
Biogen renounced ownership of their controversial anti-Alzheimer’s drug Aduhelm after years of dismal sales. The company is also halting an ongoing clinical trial set…
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data…
On July 6, 2023, the U.S. Food and Drug Administration fully approved the Alzheimer’s drug Leqembi (generic name lecanemab), a monoclonal antibody drug for…
What were the biggest breakthroughs in Alzheimer’s and dementia in 2023? Watch the video or read a transcript below. 1. The FDA grants full…
The brain’s immune system is like an orchestra. Imagine the microglia are the violinists and cellists, the astrocytes are the brass section, and various…
DEVELOPING STORY, updated 30 October, 2023: In August 2021, the biotechnology company Cassava Sciences — makers of simufilam, an experimental Alzheimer drug currently in…
At the 16th Annual Clinical Trials in Alzheimer’s Disease (CTAD) this week, T3D Therapeutics shared early data on an experimental Alzheimer’s pill they’re calling…
UPDATE: 3 March 2024, 8:14 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Dementia is most widely associated with its cognitive symptoms, like memory loss. But it often brings a host of behavioral symptoms, too, like agitation…
Alzheimer’s disease affects one in every three people over the age of 85, and the scale of the epidemic is only worsening. While there…
In January of 2023, the Food and Drug Administration approved the second anti-amyloid therapy for Alzheimer’s disease, Leqembi (generic name lecanemab). A new Alzheimer’s…
Over 55 million people worldwide have dementia. This mind-robbing condition has a huge impact on society and the economy, so scientists are working hard…
I’m writing from Amsterdam, where this past week, the Being Patient editorial team has been reporting on the biggest news from the Alzheimer’s Association…
This article was made possible through sponsorship by Lexeo Therapeutics. Being Patient’s editorial team produced the interview and article with no review/approval process by the…